Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus

Aging

Volumn 8, Issue 8, 2016, Pages 1636-1649

  Tseng, Chin Hsiao ^a,b,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Diabetes mellitus; Gastric cancer; Metformin; Taiwan

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN;

AGED; COMPLICATION; FACTUAL DATABASE; FEMALE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; RISK; RISK REDUCTION; STOMACH TUMOR; TAIWAN;

AGED; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; RISK REDUCTION BEHAVIOR; STOMACH NEOPLASMS; TAIWAN;

EID: 84987910755     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.101019     Document Type: Article

References (74)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108. doi.org/10.3322/caac.21262.
2. Tseng CH. Diabetes conveys a higher risk of gastric cancer mortality despite an age-standardised decreasing trend in the general population in Taiwan. Gut. 2011; 60:774-79. doi.org/10.1136/gut.2010.226522.
3. Tseng CH. Diabetes, insulin use, and gastric cancer: a population-based analysis of the Taiwanese. J Clin Gastroenterol. 2013; 47:e60-64. doi.org/10.1097/MCG.0b013e31827245eb.
4. Tseng CH, Tseng FH. Diabetes and gastric cancer: the potential links. World J Gastroenterol. 2014; 20:1701-11. doi.org/10.3748/wjg.v20.i7.1701.
5. Tseng CH. Diabetes, insulin use and Helicobacter pylori eradication: a retrospective cohort study. BMC Gastroenterol. 2012; 12:46. doi.org/10.1186/1471-230X-12-46.
6. Wei XL, Qiu MZ, Jin Y, Huang YX, Wang RY, Chen WW, Wang DS, Wang F, Luo HY, Zhang DS, Wang FH, Li YH, Xu RH. Hepatitis B virus infection is associated with gastric cancer in China: an endemic area of both diseases. Br J Cancer. 2015; 112:1283-90. doi.org/10.1038/bjc.2014.406.
7. Ma Z, Wang W, Jin G, Chu P, Li H. Effect of statins on gastric cancer incidence: a meta-analysis of case control studies. J Cancer Res Ther. 2014; 10:859-65. doi.org/10.4103/0973-1482.138218.
8. Hunt RH, Camilleri M, Crowe SE, El-Omar EM, Fox JG, Kuipers EJ, Malfertheiner P, McColl KE, Pritchard DM, Rugge M, Sonnenberg A, Sugano K, Tack J. The stomach in health and disease. Gut. 2015; 64:1650-68. doi.org/10.1136/gutjnl-2014-307595.
9. Sugimoto M, Yamaoka Y, Shirai N, Furuta T. Role of renin-angiotensin system in gastric oncogenesis. J Gastroenterol Hepatol. 2012; 27:442-51. doi.org/10.1111/j.1440-1746.2011.06964.x.
10. Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH. The influence of type 2 diabetes and glucoselowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res. 2012; 2012:413782. doi.org/10.1155/2012/413782 PMID:22719752.
11. Tseng CH. Use of insulin and mortality from breast cancer among Taiwanese women with diabetes. J Diabetes Res. 2015; 2015:678756. doi.org/10.1155/2015/678756 PMID:26171401.
12. Tseng CH. Prolonged use of human insulin increases breast cancer risk in Taiwanese women with type 2 diabetes. BMC Cancer. 2015; 15:846. doi.org/10.1186/s12885-015-1876-7.
13. Tseng CH. Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes. Eur J Clin Invest. 2016; 46:70-79.http://dx.doi.org/10.1111/eci.12570.
14. Tseng CH. Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes. Oncotarget. 2016; 7:24871-79; Epub ahead of print. doi.org.10.18632/oncotarget.8399.
15. Tseng CH. A review on thiazolidinediones and bladder cancer in human studies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2014; 32:1-45. doi.org/10.1080/10590501.2014.877645.
16. Tseng CH, Lee KY, Tseng FH. An updated review on cancer risk associated with incretin mimetics and enhancers. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2015; 33:67-124. dx.doi.org/10.1080/10590501.2015.1003496.
17. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330:1304-05. doi.org/10.1136/bmj.38415.708634.F7.
18. Lee KM, Lee M, Lee J, Kim SW, Moon HG, Noh DY, Han W. Enhanced anti-tumor activity and cytotoxic effect on cancer stem cell population of metforminbutyrate compared with metformin HCl in breast cancer. Oncotarget. 2016; Epub ahead of print. doi.org/10.18632/oncotarget.9522.
19. Liu Z, Qi S, Zhao X, Li M, Ding S, Lu J, Zhang H. Metformin inhibits 17β-estradiol-induced epithelialto-mesenchymal transition via βKlotho-related ERK1/2 signaling and AMPKa signaling in endometrial adenocarcinoma cells. Oncotarget. 2016; Epub ahead of print. doi.org/10.18632/oncotarget.7040.
20. Al-Wahab Z, Mert I, Tebbe C, Chhina J, Hijaz M, Morris RT, Ali-Fehmi R, Giri S, Munkarah AR, Rattan R. Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restriction. Oncotarget. 2015; 6:10908-23. doi.org/10.18632/oncotarget.3434.
21. Della Corte CM, Ciaramella V, Di Mauro C, Castellone MD, Papaccio F, Fasano M, Sasso FC, Martinelli E, Troiani T, De Vita F, Orditura M, Bianco R, Ciardiello F, Morgillo F. Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells. Oncotarget. 2016; 7:4265-78. doi.org/10.18632/oncotarget.6559.
22. Park J, Kim WG, Zhao L, Enomoto K, Willingham M, Cheng SY. Metformin blocks progression of obesityactivated thyroid cancer in a mouse model. Oncotarget. 2016; Epub ahead of print. doi.org/10.18632/oncotarget.8989.
23. Tian Y, Tang B, Wang C, Sun D, Zhang R, Luo N, Han Z, Liang R, Gao Z, Wang L. Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. Oncotarget. 2016; Epub ahead of print. doi.org/10.18632/oncotarget.10079.
24. Yue W, Zheng X, Lin Y, Yang CS, Xu Q, Carpizo D, Huang H, DiPaola RS, Tan XL. Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing antiapoptotic proteins Mcl-1 and Bcl-2. Oncotarget. 2015; 6:21208-24. doi.org/10.18632/oncotarget.4126.
25. Moon HS, Mantzoros CS. Regulation of cell proliferation and malignant potential by irisin in endometrial, colon, thyroid and esophageal cancer cell lines. Metabolism. 2014; 63:188-93. doi.org/10.1016/j.metabol.2013.10.005.
26. Yu G, Fang W, Xia T, Chen Y, Gao Y, Jiao X, Huang S, Wang J, Li Z, Xie K. Metformin potentiates rapamycin and cisplatin in gastric cancer in mice. Oncotarget. 2015; 6:12748-62. doi.org/10.18632/oncotarget.3327.
27. Akhtar N, Syed DN, Khan MI, Adhami VM, Mirza B, Mukhtar H. The pentacyclic triterpenoid, plectranthoic acid, a novel activator of AMPK induces apoptotic death in prostate cancer cells. Oncotarget. 2016; 7:3819-31. doi.org/10.18632/oncotarget.6625.
28. Liu Q, Yuan W, Tong D, Liu G, Lan W, Zhang D, Xiao H, Zhang Y, Huang Z, Yang J, Zhang J, Jiang J. Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2/PGE2/STAT3 axis. Oncotarget. 2016; 7:28235-46; Epub ahead of print. doi.org/10.18632/oncotarget.8595.
29. Gritti M, Würth R, Angelini M, Barbieri F, Peretti M, Pizzi E, Pattarozzi A, Carra E, Sirito R, Daga A, Curmi PM, Mazzanti M, Florio T. Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current. Oncotarget. 2014; 5:11252-68. doi.org/10.18632/oncotarget.2617 PMID:25361004.
30. Velez J, Pan R, Lee JT, Enciso L, Suarez M, Duque JE, Jaramillo D, Lopez C, Morales L, Bornmann W, Konopleva M, Krystal G, Andreeff M, Samudio I. Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport. Oncotarget. 2016; Epub ahead of print. doi.org/10.18632/oncotarget.9843.
31. Anisimov VN. Metformin for cancer and aging prevention: is it a time to make the long story short? Oncotarget. 2015; 6:39398-407. doi.org/10.18632/oncotarget.6347.
32. Tseng CH. Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes. PLoS One. 2014; 9:e109852. doi.org/10.1371/journal.pone.0109852.
33. Tseng CH. Metformin may reduce oral cancer risk in patients with type 2 diabetes. Oncotarget. 2016; 7:2000-08. doi.org/10.18632/oncotarget.6626.
34. Tseng CH. Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan. Eur J Endocrinol. 2012; 167:409-16. doi.org/10.1530/EJE-12-0369.
35. Tseng CH. Metformin may reduce breast cancer risk in Taiwanese women with type 2 diabetes. Breast Cancer Res Treat. 2014; 145:785-90. doi.org/10.1007/s10549-014-2985-8.
36. Tseng CH. Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan. Gynecol Oncol. 2015; 138:147-53. doi.org/10.1016/j.ygyno.2015.03.059.
37. Tseng CH. Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2015; 31:619-26. dx.doi.org/10.1002/dmrr.2649.
38. Tseng CH. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus. Eur J Cancer. 2014; 50:2831-37. doi.org/10.1016/j.ejca.2014.08.007.
39. Tseng CH. Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes. Acta Diabetol. 2014; 51:295-303. dx.doi.org/10.1007/s00592-014-0562-6.
40. Tseng CH. Use of metformin and risk of kidney cancer in patients with type 2 diabetes. Eur J Cancer. 2016; 52:19-25. doi.org/10.1016/j.ejca.2015.09.027.
41. Tseng CH. Metformin use and cervical cancer risk in female patients with type 2 diabetes. Oncotarget. 2016; Epub ahead of print. doi.org/10.18632/oncotarget.10934.
42. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011; 11:20. doi.org/10.1186/1471-2407-11-20.
43. Kim YI, Kim SY, Cho SJ, Park JH, Choi IJ, Lee YJ, Lee EK, Kook MC, Kim CG, Ryu KW, Kim YW. Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: a nationwide cohort study. Aliment Pharmacol Ther. 2014; 39:854-63. doi.org/10.1111/apt.12660.
44. Valent F. Diabetes mellitus and cancer of the digestive organs: an Italian population-based cohort study. J Diabetes Complications. 2015; 29:1056-61. dx.doi.org/10.1016/j.jdiacomp.2015.07.017.
45. Yang XL, Ma RC, So WY, Kong AP, Xu G, Chan JC. Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settingswhat, why and how? Diabetes Obes Metab. 2012; 14:579-85. doi.org/10.1111/j.1463-1326.2011.01551.x.
46. Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med. 2013; 32:2837-49. dx.doi.org/10.1002/sim.5705.
47. Huang Y, Sun J, Wang X, Tao X, Wang H, Tan W. Helicobacter pylori infection decreases metformin tolerance in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2015; 17:128-33. doi.org/10.1089/dia.2014.0203.
48. Anisimov VN. Metformin and rapamycin are masterkeys for understanding the relationship between cell senescent, aging and cancer. Aging (Albany NY). 2013; 5:337-38. doi.org/10.18632/aging.100561.
49. Moiseeva O, Deschênes-Simard X, Pollak M, Ferbeyre G. Metformin, aging and cancer. Aging (Albany NY). 2013; 5:330-31. doi.org/10.18632/aging.100556.
50. Li W, Saud SM, Young MR, Chen G, Hua B. Targeting AMPK for cancer prevention and treatment. Oncotarget. 2015; 6:7365-78. doi.org/10.18632/oncotarget.3629.
51. Yu G, Fang W, Xia T, Chen Y, Gao Y, Jiao X, Huang S, Wang J, Li Z, Xie K. Metformin potentiates rapamycin and cisplatin in gastric cancer in mice. Oncotarget. 2015; 6:12748-62. doi.org/10.18632/oncotarget.3327.
52. Wan G, Yu X, Chen P, Wang X, Pan D, Wang X, Li L, Cai X, Cao F. Metformin therapy associated with survival benefit in lung cancer patients with diabetes. Oncotarget. 2016; Epub ahead of print. doi.org/10.18632/oncotarget.8881.
53. Kato K, Gong J, Iwama H, Kitanaka A, Tani J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, Kobara H, Mori H, Himoto T, et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther. 2012; 11:549-60. doi.org/10.1158/1535-7163.MCT-11-0594.
54. Fang W, Cui H, Yu D, Chen Y, Wang J, Yu G. Increased expression of phospho-acetyl-CoA carboxylase protein is an independent prognostic factor for human gastric cancer without lymph node metastasis. Med Oncol. 2014; 31:15. doi.org/10.1007/s12032-014-0015-7.
55. Chang HR, Nam S, Kook MC, Kim KT, Liu X, Yao H, Jung HR, Lemos R Jr, Seo HH, Park HS, Gim Y, Hong D, Huh I, et al. HNF4a is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut. 2016; 65:19-32. doi.org/10.1136/gutjnl-2014-307918.
56. Han G, Gong H, Wang Y, Guo S, Liu K. AMPK/mTORmediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell. Cancer Biol Ther. 2015; 16:77-87. doi.org/10.4161/15384047.2014.987021.
57. Chen G, Feng W, Zhang S, Bian K, Yang Y, Fang C, Chen M, Yang J, Zou X. Metformin inhibits gastric cancer via the inhibition of HIF1a/PKM2 signaling. Am J Cancer Res. 2015; 5:1423-34.
58. Morsy MA, Ashour OM, Fouad AA, Abdel-Gaber SA. Gastroprotective effects of the insulin sensitizers rosiglitazone and metformin against indomethacininduced gastric ulcers in Type 2 diabetic rats. Clin Exp Pharmacol Physiol. 2010; 37:173-77. doi.org/10.1111/j.1440-1681.2009.05250.x.
59. Baraka AM, Deif MM. Role of activation of 5'-adenosine monophosphate-activated protein kinase in gastric ulcer healing in diabetic rats. Pharmacology. 2011; 88:275-83. doi.org/10.1159/000331879.
60. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci USA. 2015; 112:1809-14. doi.org/10.1073/pnas.1417636112.
61. Corominas-Faja B, Quirantes-Piné R, Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Martin-Castillo B, Micol V, Joven J, Segura-Carretero A, Menendez JA. Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging (Albany NY). 2012; 4:480-98. doi.org/10.18632/aging.100472.
62. Sheh A, Fox JG. The role of the gastrointestinal microbiome in Helicobacter pylori pathogenesis. Gut Microbes. 2013; 4:505-31. doi.org/10.4161/gmic.26205.
63. Hur KY, Lee MS. New mechanisms of metformin action: focusing on mitochondria and the gut. J Diabetes Investig. 2015; 6:600-09. doi.org/10.1111/jdi.12328.
64. Dingemanse C, Belzer C, van Hijum SA, Günthel M, Salvatori D, den Dunnen JT, Kuijper EJ, Devilee P, de Vos WM, van Ommen GB, Robanus-Maandag EC. Akkermansia muciniphila and Helicobacter typhlonius modulate intestinal tumor development in mice. Carcinogenesis. 2015; 36:1388-96. doi.org/10.1093/carcin/bgv120.
65. Tseng CH. Obesity paradox: differential effects on cancer and noncancer mortality in patients with type 2 diabetes mellitus. Atherosclerosis. 2013; 226:186-92. doi.org/10.1016/j.atherosclerosis.2012.09.004.
66. Bureau of Health Promotion. Cancer Registry Annual Report 2007. Taiwan: Department of Health, Executive Yuan, 2010. http://tcr.cph.ntu.edu.tw/uploadimages/Y96-ALL.pdf (February 22, 2016, date last accessed).
67. Parsons LS. Performing a 1:N case-control match on propensity score. http://www.google.com.tw/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CBsQFjAAahUKEwibi7HllcnIAhUDoJQKHVeZA9A&url=http%3A%2F%2Fwww2.sas.com%2Fproceedings%2Fsugi 29%2F165-29.pdf&usg=AFQjCNFOHGWYu8E8Bn4-Bo1TUiJKtT987Q (last accessed October 17, 2015).
68. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012; 35:278-80. doi.org/10.2337/dc11-1449.
69. Tseng CH. Sitagliptin increases acute pancreatitis risk within 2 years of its initiation: A retrospective cohort analysis of the National Health Insurance database in Taiwan. Ann Med. 2015; 47:561-69. doi.org/10.3109/07853890.2015.1091944.
70. Tseng CH. Sitagliptin and heart failure hospitalization in patients with type 2 diabetes. Oncotarget. 2016; Epub ahead of print. doi.org/10.18632/oncotarget.8399.
71. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer. 1997; 80:1438-47. doi.org/10.1002/(SICI)1097-0142(19971015)80:8<1438::AID-CNCR11>3.0.CO;2-6.
72. Bonovas S, Nikolopoulos GK, Bagos PG. Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebocontrolled trials. PLoS One. 2012; 7:e45259. doi.org/10.1371/journal.pone.0045259.
73. Chang L. A study of validation on comorbidity derived from claims data [Master thesis]: National Yang-Ming University; 2004. http://etd.lib.nctu.edu.tw/cgi-bin/gs32/ymgsweb.cgi/ccd=ji3XTg/search#result (Accessed: October 26, 2015).
74. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015; 34:3661-79. doi.org/10.1002/sim.6607.